RxDoctor Payments Data

Kingsley Iyamu, MD

Psychiatry · Smyrna, GANPI 1275615171

Payments from drug & device makers

$629in general payments, 2019–2025

Across 19 payments — averaging $33.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$269
  • Otsuka America Pharmaceutical, Inc.$117
  • Vanda Pharmaceuticals Inc.$63
  • Johnson & Johnson$62
  • Neurocrine Biosciences, Inc.$38
  • Lundbeck LLC$36
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$629 in reported general payments places this provider in the 55th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$83,816
Medicare patients
413
Services billed
992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$86,223
NamzaricMemantine Hcl/Donepezil Hcl202$29,808
Abilify MaintenaAripiprazole13$26,510
Risperdal ConstaRisperidone Microspheres33$22,288
Memantine Hcl1,212$21,186
NuedextaDextromethorphan Hbr/Quinidine23$8,963
Divalproex Sodium329$8,784
ExelonRivastigmine30$8,481
Donepezil Hcl1,264$7,286
Doxepin Hcl78$5,532
Clozapine57$4,214
Quetiapine Fumarate430$3,965
Escitalopram Oxalate627$3,531
Oxcarbazepine144$2,902
Mirtazapine208$2,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$38$86,22311 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$117$26,51013 claims
Johnson & JohnsonRisperdal Consta$62$22,28833 claims
Avanir Pharmaceuticals, Inc.Nuedexta$17$8,96323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →